Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
Table 3
Comparisons of characteristics between patients with clinical benefit (CR, PR, and SD) and patients without clinical benefit (PD).
Variable
N
Patients with clinical benefit ()
Patients without clinical benefit ()
value
Clinical data
Breslow index, median (mm)
10
2.44
3.99
0.134
PS > 0
10
2/6
1/4
1.000
LDH > N
10
3/6
2/4
1.0000
AJCC stage IV
10
5/6
1/4
0.191
Metastatic disease diagnosis to TIL injection, median (years)
10
2.9
4.6
0.669
Ipilimumab before TILs
10
2/6
2/4
1.000
Ipilimumab after TILs
10
2/6
1/4
1.000
TILs infused, median (×109)
10
8.1
5.5
0.609
BRAF mutation V600E
9
2/5
2/4
1.000
c-KIT mutated
10
1/6
0/4
1.000
TIL phenotypes
CD3+
9
97.70%
96.23%
0.914
CD3 + CD4+
9
56.98%
47.04%
0.914
CD3 + CD8+
9
34.58%
36.78%
0.914
CD4 + CD25+a
9
8.50%
5.56%
1.000
CD4 + CD25 + CD127lowCTLA4+
9
16.89%
19.07%
0.3524
CD4 + CD25 + CD127lowFoxp3+b
9
30.71%
20.49%
0.1714
AJCC: American Joint Committee on Cancer; CI: confidence interval; LDH: lactate dehydrogenase; PS: performance status. aPercentage among the CD3+ population. bPercentage among the CD4 + CD25+ population.
